GENFIT’s Post

📢 New Publication Our article “PCR-Based Evaluation of Viral Load Reduction in Adenoviral Conjunctivitis” has been published. 👉 Aim: To assess the efficacy of ganciclovir (GCV), povidone-iodine (PVP-I), and their combination with loteprednol etabonate (LE) in reducing viral load and improving clinical outcomes. Many thanks to my co-authors for their valuable contributions. 🔗 https://lnkd.in/d7aScTwi #Ophthalmology #Cornea #AdenoviralConjunctivitis #Research

"I think the future of Hepatic Encephalopathy is quite open. There's a lot of unmet research gaps." At GENFIT, we are committed to contributing to this future by driving scientific innovation and collaboration across the liver health ecosystem. So let's hear one last time ISHEN's president Christopher F. Rose about the future of HE management that we intend to be part of. #GENFIT #ISHEN2025 #FutureOfMedicine #HepaticEncephalopathy Karen Seto Adina S. European Liver Patients' Association - ELPA Global Liver Institute

In a new #NIHfunded study led by scientists at the Wilmer Eye Institute, Johns Hopkins Medicine, researchers say they have determined that low blood sugar, or hypoglycemia, may promote a breakdown of the blood-retinal barrier. The research provides insights into the origin of diabetic retinopathy, specifically in patients with episodes of hypoglycemia. To learn more visit: https://brnw.ch/21wW47i

Important insights from Wilmer Eye Institute on how hypoglycemia may impact diabetic retinopathy. At DRCR Retina Network, we share the commitment to advancing research that protects vision. #VisionResearch #DiabeticRetinopathy #NIHfunded

Breakthrough in tumour control 🔬 Kenneth Peuker, #UEGWeek top abstract awardee, presents his team's findings showing that calcineurin is critical for CD8 T cell metabolism, activation and expansion. ▶️Watch his recap.

Parkinson’s disease is a fatty acidopathy? - Parkinson disease (PD) and related α-synucleinopathies have increasingly been considered lipidopathies as well as proteinopathies. - Extensive evidence reviewed herein supports both physiological and pathogenic interplay between α-synuclein and fatty acids as determinants of progression from neuronal health to PD. - α-Synuclein homeostasis is affected by membrane fatty acid composition, and dysregulated fatty acid metabolism alters transient α-synuclein membrane binding, including at synaptic vesicles. - We propose that PD is a fatty acidopathy, with fatty acid side chain dyshomeostasis being a chief contributor to lipid aberrations in synucleinopathies. - The fatty acid-ome holds promise for identifying and validating PD biomarkers and therapeutic targets. https://lnkd.in/eSQhCcT4

✨Hyperphosphatemia in Kidney Failure: New Options on the Horizon Hyperphosphatemia remains a major challenge for patients with kidney failure, driving vascular calcification, cardiovascular events, bone fragility, and reduced quality of life. Traditional strategies diet, binders, and dialysis adjustments often fall short. 💡A recent AJKD mini‑review highlights Tenapanor, a novel therapy that reduces intestinal phosphate absorption via NHE3 inhibition. Evidence shows: -Effective as monotherapy and in combination with binders (AMPLIFY trial). -Reduction in pill burden, improving adherence. (It is taken twice daily, independent of food intake) -Manageable safety profile, with diarrhea as the main side effect. (If diarrhea is significant or persistent, the dosage can be decreased to improve tolerance.) The review also reminds us of ongoing debates: the limited evidence linking phosphate lowering to hard outcomes, and the balance between calcium‑based vs. non‑calcium binders. For nephrologists, Tenapanor represents an important addition to our toolkit not a replacement, but a complement to diet, binders, and dialysis. Ultimately, the goal is not just lowering phosphate, but improving survival, reducing cardiovascular risk, and enhancing quality of life for our patients. #LiveLoveMedicine #Nephrology #CKD #CKDComplications #CKD_MBD #Hyperphosphatemia #ContinuouslyUpdated ❤

🩸 Optimizing Albumin Therapy — The Missing Dose Evidence 📊 We still lack true dose-ranging RCTs comparing low, medium, and high albumin doses in cirrhosis or HRS. 📚 Landmark trials like CONFIRM, ANSWER, and ATTIRE tested other therapies — not albumin dose variation. 💡 Current regimens (1 g/kg × 2 days → 20–40 g/day) are based on physiology and pooled observations, not direct dose-response data. 🫀 “Optimized” albumin now means tailoring to volume status, inflammation, and cardiac tolerance — not simply giving more. 🎯 The next frontier is precision dosing to balance efficacy and safety in advanced liver disease. #UEG2025 #Hepatology #HRS #Cirrhosis #Albumin #Transplant #LiverFailure #MedEd

🔥 Metformin may lower the risk of post-burn hyperglycemia and modulate broader hypermetabolic response— potentially yielding better outcomes than insulin-only approaches — according to Marc Jeschke, MD, PhD, of McMaster University and colleagues. Learn more here: https://lnkd.in/eXu-HpbY

🌟 Prokera – A biologic bandage for the eye 🌟 Prokera, developed by Bio-Tissue (Miami, USA), is a therapeutic device made from human amniotic membrane that promotes healing, reduces inflammation, and protects the ocular surface. It has proven value in managing persistent epithelial defects, neurotrophic keratopathy, chemical burns, Stevens-Johnson syndrome, and other severe ocular surface diseases. As ophthalmologists, we strive to combine science and innovation to preserve vision and improve quality of life — Prokera is an excellent example of this progress. 🎥 Video courtesy of @ophthalmo_mentor #Ophthalmology #EyeCare #InnovationInMedicine #Cornea #Prokera #OcularSurfaceDisease #MedicalInnovation #VisionCare #BioTissue